Experimental arthritis: Effect on growth parameters and total skeletal calcium

Growth Hormone and IGF Research

Volumn 19, Issue 5, 2009, Pages 442-446

  Pozo, E del ^a   Zapf, J ^b   Mackenzie, A R ^d   Janner, M ^c   Perrelet, R ^a   Lippuner, K ^a   Mullis, P ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Children's Hospital   (Switzerland)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Experimental arthritis; Growth; Skeletal calcium

Indexed keywords

CALCIUM; CYCLOSPORIN A; GROWTH HORMONE; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BONE GROWTH; BONE MINERAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GROWTH RETARDATION; INFLAMMATION; NONHUMAN; OSTEOPOROSIS; PAW EDEMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; VERTEBRA;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BODY WEIGHT; BONE DENSITY; BONE DEVELOPMENT; CALCIUM; DISEASE MODELS, ANIMAL; FEMALE; GROWTH DISORDERS; GROWTH HORMONE; RATS;

EID: 70349304207     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2009.01.003     Document Type: Article

References (41)

1. White P.H. Growth abnormalities in children with juvenile rheumatoid arthritis. Clin. Orth. Rel. Res. 259 (1990) 46-50
2. Davies U.M., Jones J., Reeve J., et al. Juvenile rheumatoid arthritis. Effects of disease activity and recombinant human growth hormone on insulin-like growth factor 1, insulin-like growth factor binding proteins 1 and 3 and osteocalcin. Arthritis Rheum. 40 (1997) 332-340
3. Weiss J.E., and Ilowite N.T. Juvenile idiopathic arthritis. Pediatr. Clin. N. Am. 52 (2005) 413-442
4. Zak M., Müller J., and Karup Pedersen F. Final height, armspan, subischial leg length and body proportions in juvenile chronic arthritis. A long-term follow-up study. Horm. Res. 52 (1999) 80-85
5. Ansell B.M., and Kent P. Radiological changes in juvenile chronic polyarthritis. Skeletal Radiol. 1 (1977) 129-144
6. Dequeker J., and Geusens P. Osteoporosis and arthritis. Ann. Rheum. Dis. 49 (1990) 276-280
7. Sullivan K.E. Inflammation in juvenile idiopathic arthritis. Pediat. Clin. N. Am. 52 (2005) 335-357
8. del Pozo E., and Zapf J. Skeletal growth and bone density as sensitive parameters in experimental arthritis: effect of cyclosporin A. Bone 15 (1994) 625-628
9. del Pozo E., Elford P., Perrelet R., et al. Prevention of adjuvant arthritis by cyclosporine in rats. Sem. Arthritis Rheum. 21 Suppl. 3 (1992) 23-29
10. López-Calderón A., Soto L., and Martín A.I. Chronic inflammation inhibits GH secretion and alters the serum insulin-like growth factor system in rats. Life Sci. 65 (1999) 2049-2060
11. Soto L., Martín A.I., Vara E., and López-Calderón A. Cyclosporin A treatment is able to revert the decrease in circulating GH and IGF-1 and the increase in IGFBPs induced by adjuvant arthritis. Horm. Metab. Res. 33 (2001) 590-595
12. Borel J.F., Wiesinger D., and Gubler H.U. Effect of the antilymphocyte agent cyclosporin A in chronic inflammation. Eur. J. Rheumatol. Inflamm. 1 (1978) 237-241
13. Casez J.P., Muehlbauer R.C., Lippuner K., Kelly T., Fleisch H., and Jaeger P.H. Dual-energy X-ray absorptiometry for measuring total bone mineral content in the rat: study of accuracy and precision. Bone Miner. 26 (1994) 61-68
14. Zapf J., Hauri C., Waldvogel M., et al. Recombinant human insulin-like growth factor I induces its own specific carrier protein in hypophysectomized and diabetic rats. Proc. Natl. Acad. Sci. USA 86 (1989) 3813-3817
15. del Pozo E., Graeber M., Elford P., and Payne T. Regression of bone and cartilage loss in adjuvant arthritic rats after treatment with cyclosporin A. Arthritis Rheum. 33 (1990) 247-252
16. Davies U.M., Rooney M., Preece M.A., Ansell B.M., and Woo P. Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone. J. Rheumatol. 21 (1994) 153-158
17. Davies U.M., Jones J., Reeve J., et al. Juvenile rheumatoid arthritis. Effects of disease activity and recombinant human growth hormone on insulin-like growth factor 1, insulin-like growth factor binding proteins 1 and 3 and osteocalcin. Arthritis Rheum. 40 (1997) 332-340
18. Ibáñez I., de Cáceres M.A., Villanúa I., Soto A.I., Martín A., and López-Calderón A. IGF-1 and IGF-1-binding proteins in rats with adjuvant-induced arthritis given recombinant human growth hormone. J. Endocrinol. 165 (2000) 537-544
19. Yakar S., Rosen C.J., Beamer W.G., et al. Circulating levels of IGF-1 directly regulate bone growth and density. J. Clin. Invest. 110 (2002) 771-781
20. Hunziker E.B., Wagner J., and Zapf J. Differential effect of insulin-like growth factor I and growth hormone on developmental stages of rat growth plate Chondrocytes in vivo. J. Clin. Invest. 93 (1994) 1078-1086
21. Reinecke M., Schmid A.C., Heyberger-Meyer B., Hunziker E.B., and Zapf J. Effect of growth hormone and insulin-like growth factor I (IGF-I) on the expression of IGF-I messenger ribonucleic acid and peptide in rat tibial growth plate and articular chondrocytes in vivo. Endocrinology 141 (2000) 2847-2853
22. Ibáñez I., de Cáceres T., Priego A.I., Martín A., López-Calderón M.A., and Villanúa M.A. The inhibition of inducible nitric oxide synthetase reverts arthritic-induced decrease in pituitary growth hormone mRNA but not in liver insulin-like growth factor 1 mRNA expression. J. Neuroendocrinol. 15 (2003) 1178-1184
23. Lazzerini P.E., Selvi E., Lorenzini S., et al. Homocysteine enhances cytokine production in cultured synoviocytes from rheumatoid arthritis patients. Clin. Exp. Rheumatol. 24 (2006) 387-393
24. MacRae V.E., Wong S.C., Farquharson C., and Ahmed S.F. Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases. Int. J. Mol. Med. 18 (2006) 1011-1018
25. del Pozo E., Popp A.W., Mackenzie A., Perrelet R., Lamberts S.W.J., and Lippuner K. Graded doses of recombinant interleukin-1beta induce generalized osteopenia in rats without altering skeletal growth and joint integrity. Horm. Res. 64 (2005) 88-95
26. Pettipher E.R., Higgs G.A., and Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc. Natl. Acad. Sci. USA 83 (1986) 8749-8753
27. Dingle J.T., Page Thomas D.P., and Hazleman B. The role of cytokines in arthritic diseases: in vitro and in vivo measurements of cartilage degradation. Int. J. Tissue React. 9 (1987) 349-354
28. Rifas L. Bone and cytokines: beyond IL-1, IL-6 and TNF-alpha. Calcif. Tissue Int. 64 (1999) 1-7
29. Hawkins P.N., Lachmann H.J., and McDermott M.F. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. New Engl. J. Med. 348 (2003) 2583-2584
30. Leslie K.S., Lachmann H.J., Bruning E., et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch. Dermatol. 142 (2006) 1591-1597
31. Cohen S., Hurd E., Cush J., et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist In combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46 (2002) 614-624
32. Jiang Y., Genant H.K., Watt I., et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43 (2000) 1001-1009
33. Minne H.W., Pfeilschifter J., Scharla S., et al. Inflammation-mediated osteopenia in the rat: a new animal model for pathological loss of bone mass. Endocrinology 115 (1984) 50-54
34. Bechtold S., Ripperger P., Hafner R., Said E., and Schwarz H.P. Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J. Pediatr. 143 (2003) 512-519
35. Hirayama T., Danks L., Sabokbar A., and Athanason N.A. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. Rheumatology 41 (2002) 1232-1239
36. Stashenko P., Dewhirst F.E., Rooney M.L., Desjardins L.A., and Heeley J.D. Interleukin-1 is a potent inhibitor of bone formation in vitro. J. Bone Miner. Res. 2 (1987) 559-565
37. Holstead Jones D., Kong Y.-Y., and Penninger J.M. Role of RANKL and RANK in bone loss and arthritis. Ann. Rheum. Dis. 61 Suppl. II (2002) ii32-ii39
38. Gravallese E.M. Bone destruction in arthritis. Ann. Rheum. Dis. 61 Suppl. II (2002) ii84-ii86
39. Panayi G.S., Lanchbury J.S., and Kingsley G.H. The importance of the T-cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum. 35 (1992) 729-735
40. Kong Y.-Y., Feige U., Sarosi I., et al. Activated T-cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 (1999) 304-309
41. Rehman Q., and Lane N.E. Bone loss therapeutic approaches for preventing bone loss in inflammatory arthritis. Arthritis Res. 3 (2001) 221-227